Merck raises full-year guidance despite mixed Q3

Shares in Merck (NYSE:MRK) slipped in pre-market activity today after the pharmaceutical company beat earnings estimates but missed sales expectations on Wall Street with its third quarter results.

The Kenilworth, N.J.-based company posted a loss of -$51 million, or -2¢ per share, on sales of $10.33 billion for the 3 months ended Sept. 30.

Get the full story at our sister site, Drug Delivery Business News.

The post Merck raises full-year guidance despite mixed Q3 appeared first on MassDevice.

from MassDevice http://ift.tt/2yR0hMJ